Neutral
Assessing Nanobiotix (ENXTPA:NANO) Valuation After FDA Protocol Amendment For Key Phase 3 Cancer Study
Nanobiotix is under scrutiny after the FDA approved a protocol amendment for its pivotal Phase 3 NANORAY-312 study. Despite a significant recent share...